Brief Title: STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Dose limiting toxicities (DLTs)

Primary Outcome 1 - Timeframe: 1 cycle (21 days)

Primary Outcome 2 - Measure: Adverse events

Primary Outcome 2 - Timeframe: From 1st dose of STK-012 through 90 days after last dose of STK-012

CONDITION

• A
• N
• H
• M
• R
• C
• M
• G
• G
• U
• M

ELIGIBILITY

Selected Inclusion Criteria
1. Patients must have selected tumor types and must have progressed after standard of care treatment, or be intolerant to treatment, or refused standard treatment.

- 2. Patients must be amenable to a fresh tissue biopsy, unless medically contraindicated.

- 3. Patients with central nervous system (CNS) metastases must have been treated and be asymptomatic.
Selected Exclusion Criteria:
1. Received systemic anti-cancer therapy within 3 weeks of the first dose of study treatment or small molecule kinase inhibitors within 6 elimination half-lives of the first dose of study treatment.

- 2. Received radiotherapy within 2 weeks of the first dose of study treatment.

- 3. Received prior IL-2-based or IL-15-based cytokine therapy.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: N/A

Role: N/A

Affiliation: N/A

Overall Contact

Name: N/A

Phone: 6

Email: c

LOCATION